Transition Agreement, dated March 31, 2021, by and between Allena Pharmaceuticals, Inc. and Edward Wholihan
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: April 2, 2021
Allena Pharmaceuticals, Inc.
/s/ Richard Katz
Chief Financial Officer
makes a similar move, sign up!
Other recent filings from the company include the following: